{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:01:14Z","timestamp":1790283674704,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014418","name":"Harbin Medical University Cancer Hospital","doi-asserted-by":"publisher","award":["JJZD2024-16"],"award-info":[{"award-number":["JJZD2024-16"]}],"id":[{"id":"10.13039\/100014418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017366","name":"Key Research and Development Program of Heilongjiang","doi-asserted-by":"publisher","award":["2023ZX06C09"],"award-info":[{"award-number":["2023ZX06C09"]}],"id":[{"id":"10.13039\/100017366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303742"],"award-info":[{"award-number":["82303742"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62372141"],"award-info":[{"award-number":["62372141"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["academicradiology.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Academic Radiology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.acra.2026.08.115","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:38:41Z","timestamp":1789731521000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting Response to Somatostatin Analog Therapy in GEP-NET Liver Metastases: A Machine Learning Approach with \u2076\u2078Ga-DOTATATE and \u00b9\u2078F-FDG PET\/CT"],"prefix":"10.1016","author":[{"given":"Junhao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingrong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanlin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinquan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongxue","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kezheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3128-1385","authenticated-orcid":false,"given":"Haibo","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.acra.2026.08.115_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ecl.2010.12.005","article-title":"The epidemiology of gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Lawrence","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"10","key":"10.1016\/j.acra.2026.08.115_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.acra.2026.08.115_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.15798","article-title":"Epidemiology of neuroendocrine neoplasms in the US","volume":"8","author":"Dasari","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.acra.2026.08.115_bib4","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","article-title":"Recommendations for management of patients with neuroendocrine liver metastases","volume":"15","author":"Frilling","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.acra.2026.08.115_bib5","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/cncr.28760","article-title":"Therapeutic strategies for neuroendocrine liver metastases","volume":"121","author":"Frilling","year":"2015","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.acra.2026.08.115_bib6","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1245\/s10434-020-08787-x","article-title":"The landmark series: neuroendocrine tumor liver metastases","volume":"27","author":"Gangi","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.acra.2026.08.115_bib7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11864-017-0514-9","article-title":"Update in the therapy of advanced neuroendocrine tumors","volume":"18","author":"Uri","year":"2017","journal-title":"Curr Treat Options Oncol"},{"issue":"28","key":"10.1016\/j.acra.2026.08.115_bib8","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.acra.2026.08.115_bib9","first-page":"1556","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.acra.2026.08.115_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of (177)Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.acra.2026.08.115_bib11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000475526","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues","volume":"105","author":"Hicks","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"2","key":"10.1016\/j.acra.2026.08.115_bib12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2967\/jnumed.119.240911","article-title":"NANETS\/SNMMI consensus statement on patient selection and appropriate use of (177)Lu-DOTATATE peptide receptor radionuclide therapy","volume":"61","author":"Hope","year":"2020","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.acra.2026.08.115_bib13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.acra.2026.08.115_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100780","article-title":"Optimal approaches to grading entero-pancreatic neuroendocrine tumors using Ki-67 proliferation index (hotspot and whole slide digital quantitative analysis)","author":"Abukhiran","year":"2025","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.acra.2026.08.115_bib15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/PAS.0000000000002196","article-title":"Ki-67 proliferation index is associated with tumor grade and survival in pleural epithelioid mesotheliomas","volume":"48","author":"Galeano","year":"2024","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.acra.2026.08.115_bib16","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1007\/s11517-024-03045-8","article-title":"Automated AI-based grading of neuroendocrine tumors using Ki-67 proliferation index: comparative evaluation and performance analysis","volume":"62","author":"Y\u00fccel","year":"2024","journal-title":"Med Biol Eng Comput"},{"issue":"1","key":"10.1016\/j.acra.2026.08.115_bib17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3390\/cancers14010162","article-title":"Correlation of somatostatin receptor 1-5 expression, [(68)Ga]Ga-DOTANOC, [(18)F]F-FDG PET\/CT and clinical outcome in a prospective cohort of pancreatic neuroendocrine neoplasms","volume":"14","author":"Majala","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.acra.2026.08.115_bib18","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1309\/AJCPQ55SKOCYFZHN","article-title":"Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors","volume":"143","author":"Shi","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.acra.2026.08.115_bib19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/modpathol.2008.177","article-title":"Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors","volume":"22","author":"Couvelard","year":"2009","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.acra.2026.08.115_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061861","article-title":"Tumour heterogeneity and the consequent practical challenges in the management of gastroenteropancreatic neuroendocrine neoplasms","volume":"15","author":"Reccia","year":"2023","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.acra.2026.08.115_bib21","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2967\/jnumed.120.256727","article-title":"Quantitative (68)Ga-DOTATATE PET\/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with (177)Lu-DOTATATE","volume":"62","author":"Ortega","year":"2021","journal-title":"J Nucl Med"},{"issue":"13","key":"10.1016\/j.acra.2026.08.115_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13132154","article-title":"Somatostatin receptor targeted PET-CT and its role in the management and theranostics of gastroenteropancreatic neuroendocrine neoplasms","volume":"13","author":"Adnan","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.acra.2026.08.115_bib23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2021.01.008","article-title":"Consensus on molecular imaging and theranostics in neuroendocrine neoplasms","volume":"146","author":"Ambrosini","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.acra.2026.08.115_bib24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13550-020-00651-z","article-title":"Tumour-to-liver ratio determined by [(68)Ga]Ga-DOTA-TOC PET\/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours","volume":"10","author":"Kim","year":"2020","journal-title":"EJNMMI Res"},{"issue":"14","key":"10.1016\/j.acra.2026.08.115_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15143581","article-title":"Prognostic implications of PET-derived tumor volume and uptake in patients with neuroendocrine tumors","volume":"15","author":"Weber","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.acra.2026.08.115_bib26","first-page":"2022","article-title":"The diagnostic and grading accuracy of 68Ga-DOTATATE and 18F-FDG PET\/MR for pancreatic neuroendocrine neoplasms","volume":"12","author":"Zhou","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.acra.2026.08.115_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1634\/theoncologist.2020-0165","article-title":"68) Ga-DOTATATE positron emission tomography-computed tomography quantification predicts response to somatostatin analog therapy in gastroenteropancreatic neuroendocrine tumors","volume":"26","author":"Lee","year":"2021","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.acra.2026.08.115_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17121937","article-title":"Somatostatin receptor expression of gastroenteropancreatic neuroendocrine tumors: a comprehensive analysis in the era of somatostatin receptor PET imaging","volume":"17","author":"Maratta","year":"2025","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.acra.2026.08.115_bib29","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.2967\/jnumed.119.241414","article-title":"Prognostic value of (18)F-FDG PET\/CT in a large cohort of patients with advanced metastatic neuroendocrine neoplasms treated with peptide receptor radionuclide therapy","volume":"61","author":"Zhang","year":"2020","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.acra.2026.08.115_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081813","article-title":"Clinical utility of (18)F-FDG PET in neuroendocrine tumors prior to peptide receptor radionuclide therapy: a systematic review and meta-analysis","volume":"13","author":"Alevroudis","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.acra.2026.08.115_bib31","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41416-022-02061-5","article-title":"Dual [(68)Ga]DOTATATE and [(18)F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score","volume":"128","author":"Chan","year":"2023","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.acra.2026.08.115_bib32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2967\/jnumed.116.178095","article-title":"Comparison of the impact of 68Ga-DOTATATE and 18F-FDG PET\/CT on clinical management in patients with neuroendocrine tumors","volume":"58","author":"Panagiotidis","year":"2017","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.acra.2026.08.115_bib33","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ijrobp.2017.12.268","article-title":"Challenges and promises of PET radiomics","volume":"102","author":"Cook","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.acra.2026.08.115_bib34","first-page":"127","article-title":"Artificial intelligence in cancer imaging: clinical challenges and applications","volume":"69","author":"Bi","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.acra.2026.08.115_bib35","doi-asserted-by":"crossref","first-page":"29s","DOI":"10.2967\/jnumed.118.220590","article-title":"Artificial intelligence in nuclear medicine","volume":"60","author":"Nensa","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.acra.2026.08.115_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.media.2022.102470","article-title":"Explainable artificial intelligence (XAI) in deep learning-based medical image analysis","volume":"79","author":"van der Velden","year":"2022","journal-title":"Med Image Anal"},{"issue":"1","key":"10.1016\/j.acra.2026.08.115_bib37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/RLU.0000000000003937","article-title":"The combined interpretation of 68Ga-DOTATATE PET\/CT and 18F-FDG PET\/CT in metastatic gastroenteropancreatic neuroendocrine tumors: a classification system with prognostic impact","volume":"47","author":"Hayes","year":"2022","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.acra.2026.08.115_bib38","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2340389","article-title":"Clinical and prognostic value of PET\/CT imaging with combination of (68)Ga-DOTATATE and (18)F-FDG in gastroenteropancreatic neuroendocrine neoplasms","volume":"2018","author":"Zhang","year":"2018","journal-title":"Contrast Media Mol Imaging"},{"issue":"11","key":"10.1016\/j.acra.2026.08.115_bib39","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1007\/s00259-019-04455-9","article-title":"Prognostic value of somatostatin receptor expressing tumor volume calculated from (68)Ga-DOTATATE PET\/CT in patients with well-differentiated neuroendocrine tumors","volume":"46","author":"Toriihara","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.acra.2026.08.115_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17030434","article-title":"68)Ga-DOTATATE PET\/CT in the initial staging of well-differentiated gastroenteropancreatic and non-gastroenteropancreatic neuroendocrine tumors: results of a prospective registry","volume":"17","author":"Metser","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.acra.2026.08.115_bib41","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/RLU.0000000000005231","article-title":"Heterogeneous uptake of 68 Ga-DOTATATE and 18 F-FDG in initial diagnosed neuroendocrine tumors patients: which patients are suitable for dual-tracer PET imaging?","volume":"49","author":"Zhou","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"3","key":"10.1016\/j.acra.2026.08.115_bib42","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/onco5030036","article-title":"Imaging of liver metastases from GEP-NETs: a narrative review","volume":"5","author":"Posa","year":"2025","journal-title":"Onco"}],"container-title":["Academic Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633226007300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633226007300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:24:53Z","timestamp":1790281493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1076633226007300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"alternative-id":["S1076633226007300"],"URL":"https:\/\/doi.org\/10.1016\/j.acra.2026.08.115","relation":{},"ISSN":["1076-6332"],"issn-type":[{"value":"1076-6332","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting Response to Somatostatin Analog Therapy in GEP-NET Liver Metastases: A Machine Learning Approach with \u2076\u2078Ga-DOTATATE and \u00b9\u2078F-FDG PET\/CT","name":"articletitle","label":"Article Title"},{"value":"Academic Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acra.2026.08.115","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Association of Academic Radiology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}